uniQure to Participate in Multiple Upcoming Industry Conferences in April

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced its participation in multiple upcoming virtual investor and scientific conferences. Key events include the Guggenheim Healthcare Talks on April 1, where management will engage in discussions on gene therapy challenges. Following this, the Wells Fargo Corporate Access Days will take place from April 6-8, and the Needham Virtual Healthcare Conference from April 12-15. Additional panels will cover topics related to Huntington's disease and patient advocacy. The company's pipeline focuses on therapies for various severe conditions including hemophilia and Huntington's disease.

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

• Virtual Guggenheim Healthcare Talks│2021 Genomic Medicines & Rare Disease, April 1, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 1.
    
    
  • Matt Kapusta, chief executive officer, will participate on a panel discussion entitled, “The Low-Hanging Fruit in Gene Therapy Might Be Hard to Reach – Challenges for Hemophilia A and B” on Thursday, April 1 from 10:00 to 10:50 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
  • Ricardo Dolmetsch, Ph.D., president of research and development, will participate in a panel discussion entitled, “An Idea Whose Time has Come – Disease Modifying Therapies for Huntington’s Disease” later the same day from 3:00 to 3:50 p.m. ET.
    
    
• Wells Fargo Corporate Access Days, April 6-8, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, April 6.
    
    
• Professional Patient Advocates in Life Sciences, April 13, 2021
  
  
  • Daniel Leonard, senior director of global patient advocacy, will participate on a virtual panel discussion entitled, “Building an Internal Patient Advocacy & HR Relationship Series – Part 1: Journey to Patient Advocacy” starting at 2:00 p.m. ET on Tuesday, April 13.
    

• 20^th Annual Needham Virtual Healthcare Conference, April 12 - 15, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings throughout the day on Thursday, April 15.
    
    
  • A company presentation with Matt Kapusta will take place the same day from 3:45 to 4:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• Chardan 5^th Annual Genetic Medicines Manufacturing Summit, April 26 - 27, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings on Tuesday, April 27.
    
    
  • A fireside chat with Matt Kapusta will take place the same day from 1:45 to 2:25 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.
    
    
• Kempen Life Sciences Conference – 2021 Thematic Virtual Series “Cell, Gene & RNA based companies,” April 28, 2021
  
  
  • Members of uniQure’s management team will participate in virtual one-on-one investor meetings on Wednesday, April 28.
    
    
• CHDI’s 16^th Annual Huntington’s Disease Therapeutics Conference, April 27-29, 2021
  
  
  • David Cooper, M.D., vice president of clinical research CNS, will present in the clinical stage interventional programs session on Thursday, April 29 between 10:00 a.m. and 12:30 p.m. ET. His presentation is entitled, “Updates on HD-GeneTRX-1: A Phase 1-2 Clinical Trial of CNS-Administered Gene Therapy (AMT-130) for Early-Stage HD.” Following the pre-recorded presentation, Dr. Cooper will be available for live Q&A.
    
    
  • Astrid Valles-Sanchez, Ph.D., senior scientist at uniQure, will have a poster presentation entitled, “Lowering the Pathogenic Exon1 HTT Fragment by AAV5-miHTT Gene Therapy,” during the conference dates.
    
    
• World Orphan Drug Congress, April 28, 2021
  
  
  • Nick Li, Ph.D., M.B.A., senior director, global/US market access lead, will participate on a panel entitled “Pricing & Reimbursement for Rare Diseases in the United States” starting at 3:00 p.m. ET on Wednesday, April 28.
    

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria E. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What will uniQure present at the Guggenheim Healthcare Talks on April 1, 2021?

At the Guggenheim Healthcare Talks on April 1, 2021, uniQure will discuss challenges in gene therapy for hemophilia A and B, featuring CEO Matt Kapusta in a panel discussion.

When will uniQure participate in the Wells Fargo Corporate Access Days?

uniQure will participate in the Wells Fargo Corporate Access Days from April 6 to 8, 2021, with one-on-one investor meetings scheduled for April 6.

What topics will uniQure cover at the Needham Virtual Healthcare Conference?

During the Needham Virtual Healthcare Conference from April 12 to 15, 2021, uniQure's management will hold one-on-one investor meetings, and CEO Matt Kapusta will present on April 15.

Who will represent uniQure at the CHDI’s Huntington’s Disease Therapeutics Conference?

At CHDI’s 16th Annual Huntington’s Disease Therapeutics Conference on April 27-29, 2021, Dr. David Cooper will present on the Phase 1-2 clinical trial for gene therapy in Huntington’s disease.

What key themes will be discussed at the World Orphan Drug Congress on April 28, 2021?

At the World Orphan Drug Congress on April 28, 2021, uniQure's Nick Li will participate in a panel discussing pricing and reimbursement for rare diseases.